|
|||||
|
|
Secukinumab for moderate-to-severe palmoplantar pustular psoriasis: Results of the 2PRECISE study |
|
| Authors: | Ulrich Mrowietz Hervé Bachelez A. David Burden Michael Rissler Christian Sieder Roberto Orsenigo Kamel Chaouche-Teyara |
| Affiliation: | 1. Psoriasis-Center, Department of Dermatology, University Medical Center, Schleswig-Holstein, Campus Kiel, Germany;2. Service de Dermatologie, AP-HP Hôpital Saint-Louis, Sorbonne Paris Cité Université Paris Diderot, Paris, France;3. INSERM UMR1163, Institut Imagine, Paris, France;4. Institute of Infection Inflammation and Immunity, University of Glasgow, Glasgow, United Kingdom;5. Novartis Pharma AG, Basel, Switzerland;6. Novartis Farma S.p.A, Origgio, Italy |
| Abstract: | |
| Keywords: | palmoplantar pustular psoriasis PPPASI75 quality of life secukinumab randomized controlled trial AE adverse event DLQI Dermatology Life Quality Index IL interleukin OR odds ratio PPP palmoplantar pustular psoriasis PPPASI75 75% improvement from baseline in palmoplantar Psoriasis Area and Severity Index score TP1 treatment period 1 TP2 treatment period 2 WPAI-PSO Work Productivity and Activity Impairment Questionnaire-Psoriasis |
| 本文献已被 ScienceDirect 等数据库收录！ | |